Temat: "Spike Glycoprotein, Coronavirus" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Differential laboratory passaging of SARS-CoV-2 viral stocks impacts the in vitro assessment of neutralizing antibodies.
Autorzy:: Avila-Herrera A; Lawrence Livermore National Laboratory, Computing Directorate, Global Security Computing Applications Division, Livermore, California, United States of America.
Kimbrel JA; Lawrence Livermore National Laboratory, Physical and Life Sciences Directorate, Biosciences and Biotechnology Division, Livermore, California, United States of America.
Manuel Martí J; Lawrence Livermore National Laboratory, Computing Directorate, Global Security Computing Applications Division, Livermore, California, United States of America.
Thissen J; Lawrence Livermore National Laboratory, Physical and Life Sciences Directorate, Biosciences and Biotechnology Division, Livermore, California, United States of America.
Saada EA; Lawrence Livermore National Laboratory, Physical and Life Sciences Directorate, Biosciences and Biotechnology Division, Livermore, California, United States of America.
Weisenberger T; Lawrence Livermore National Laboratory, Physical and Life Sciences Directorate, Biosciences and Biotechnology Division, Livermore, California, United States of America.
Arrildt KT; Lawrence Livermore National Laboratory, Physical and Life Sciences Directorate, Biosciences and Biotechnology Division, Livermore, California, United States of America.
Segelke BW; Lawrence Livermore National Laboratory, Physical and Life Sciences Directorate, Biosciences and Biotechnology Division, Livermore, California, United States of America.
Allen JE; Lawrence Livermore National Laboratory, Computing Directorate, Global Security Computing Applications Division, Livermore, California, United States of America.
Zemla A; Lawrence Livermore National Laboratory, Computing Directorate, Global Security Computing Applications Division, Livermore, California, United States of America.
Borucki MK; Lawrence Livermore National Laboratory, Physical and Life Sciences Directorate, Biosciences and Biotechnology Division, Livermore, California, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2024 Jan 25; Vol. 19 (1), pp. e0289198. Date of Electronic Publication: 2024 Jan 25 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: Antibodies, Neutralizing*
COVID-19*
Humans ; SARS-CoV-2/genetics ; Antibodies, Viral ; Neutralization Tests ; Immune Sera ; Spike Glycoprotein, Coronavirus/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.
Autorzy:: Park YJ; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.
Pinto D; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.
Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
De Marco A; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Benigni F; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Zatta F; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Silacci-Fregni C; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Bassi J; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Addetia A; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Stewart C; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Giurdanella M; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Saliba C; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Guarino B; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Schmid MA; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Franko NM; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Logue JK; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Dang HV; Vir Biotechnology, San Francisco, CA, USA.
Hauser K; Vir Biotechnology, San Francisco, CA, USA.
di Iulio J; Vir Biotechnology, San Francisco, CA, USA.
Rivera W; Vir Biotechnology, San Francisco, CA, USA.
Schnell G; Vir Biotechnology, San Francisco, CA, USA.
Rajesh A; Vir Biotechnology, San Francisco, CA, USA.
Zhou J; Vir Biotechnology, San Francisco, CA, USA.
Farhat N; Vir Biotechnology, San Francisco, CA, USA.
Kaiser H; Vir Biotechnology, San Francisco, CA, USA.
Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA, USA.
Noack J; Vir Biotechnology, San Francisco, CA, USA.
Lempp FA; Vir Biotechnology, San Francisco, CA, USA.
Janer J; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Abdelnabi R; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Maes P; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Ferrari P; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Ceschi A; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland.
Giannini O; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
de Melo GD; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Kergoat L; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Bourhy H; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Neyts J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Soriaga L; Vir Biotechnology, San Francisco, CA, USA.
Purcell LA; Vir Biotechnology, San Francisco, CA, USA.
Snell G; Vir Biotechnology, San Francisco, CA, USA.
Whelan SPJ; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Lanzavecchia A; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Virgin HW; Vir Biotechnology, San Francisco, CA, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Piccoli L; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Chu HY; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Pizzuto MS; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Corti D; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.; Pokaż więcej
Źródło:: Science (New York, N.Y.) [Science] 2022 Nov 11; Vol. 378 (6620), pp. 619-627. Date of Electronic Publication: 2022 Oct 20.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Antibodies, Neutralizing*/immunology
Antibodies, Viral*/immunology
Antibody Formation*
COVID-19*/immunology
SARS-CoV-2*/genetics
SARS-CoV-2*/immunology
Spike Glycoprotein, Coronavirus*
Immune Evasion*
Humans ; Neutralization Tests ; Immunologic Memory ; Memory B Cells/immunology
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines.
Autorzy:: Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Addetia A; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Dang HV; Vir Biotechnology, San Francisco, CA 94158, USA.
Stewart C; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Brown JT; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Sharkey WK; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.
Mazzitelli IG; Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Buenos Aires C1121ABG, Argentina.
Logue JK; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
Franko NM; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
Czudnochowski N; Vir Biotechnology, San Francisco, CA 94158, USA.
Powell AE; Vir Biotechnology, San Francisco, CA 94158, USA.
Dellota E Jr; Vir Biotechnology, San Francisco, CA 94158, USA.
Ahmed K; Departments of Paediatrics and Child Health and Biological and Biomedical Sciences, Aga Khan University, Karachi 74800, Pakistan.
Ansari AS; Departments of Paediatrics and Child Health and Biological and Biomedical Sciences, Aga Khan University, Karachi 74800, Pakistan.
Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Gori A; Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.; Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy.
Bandera A; Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.; Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy.
Posavad CM; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Dan JM; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA 92037, USA.
Zhang Z; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Weiskopf D; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Sette A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA 92037, USA.
Crotty S; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA 92037, USA.
Iqbal NT; Departments of Paediatrics and Child Health and Biological and Biomedical Sciences, Aga Khan University, Karachi 74800, Pakistan.
Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.
Geffner J; Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Buenos Aires C1121ABG, Argentina.
Snell G; Vir Biotechnology, San Francisco, CA 94158, USA.
Grifantini R; INGM, Istituto Nazionale Genetica Molecolare 'Romeo ed Enrica Invernizzi,' Milan, Italy.
Chu HY; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.; Pokaż więcej
Źródło:: Science (New York, N.Y.) [Science] 2022 Aug 19; Vol. 377 (6608), pp. 890-894. Date of Electronic Publication: 2022 Jul 19.
Typ publikacji:: Journal Article
MeSH Terms:: Antibodies, Neutralizing*/blood
Antibodies, Neutralizing*/immunology
Antibodies, Viral*/blood
Antibodies, Viral*/immunology
COVID-19*/blood
COVID-19*/prevention & control
COVID-19 Vaccines*/immunology
SARS-CoV-2*/immunology
Spike Glycoprotein, Coronavirus*/genetics
Spike Glycoprotein, Coronavirus*/immunology
Humans ; Immunization, Secondary
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Correlates of protection against SARS-CoV-2 infection and COVID-19 disease.
Autorzy:: Goldblatt D; Great Ormond Street Institute of Child Health, University College London, London, UK.
Alter G; Massachusetts General Hospital, Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
Crotty S; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, California, USA.; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego (UCSD), La Jolla, California, USA.
Plotkin SA; University of Pennsylvania, Vaxconsult, Doylestown, Pennsylvania, USA.; Pokaż więcej
Źródło:: Immunological reviews [Immunol Rev] 2022 Sep; Vol. 310 (1), pp. 6-26. Date of Electronic Publication: 2022 Jun 05.
Typ publikacji:: Journal Article; Review; Research Support, N.I.H., Extramural
MeSH Terms:: Antibodies, Neutralizing*/immunology
Antibodies, Viral*/immunology
COVID-19*/immunology
COVID-19*/prevention & control
SARS-CoV-2*/immunology
Spike Glycoprotein, Coronavirus*/immunology
Epitopes/immunology ; Humans

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models.
Autorzy:: Cohen AA; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
van Doremalen N; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Greaney AJ; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.; Department of Genome Sciences and Medical Scientist Training Program, University of Washington, Seattle, WA 98195, USA.
Andersen H; BIOQUAL, Rockville, MD, USA.
Sharma A; BIOQUAL, Rockville, MD, USA.
Starr TN; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.; Department of Genome Sciences and Medical Scientist Training Program, University of Washington, Seattle, WA 98195, USA.
Keeffe JR; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Fan C; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Schulz JE; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Gnanapragasam PNP; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Kakutani LM; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
West AP Jr; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Saturday G; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Lee YE; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Gao H; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Jette CA; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Lewis MG; BIOQUAL, Rockville, MD, USA.
Tan TK; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK.
Townsend AR; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK.; Chinese Academy of Medical Sciences, Oxford Institute, University of Oxford, Oxford OX3 9DS, UK.
Bloom JD; Basic Sciences Division and Computational Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.; Howard Hughes Medical Institute, Seattle, WA 98109, USA.
Munster VJ; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Bjorkman PJ; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.; Pokaż więcej
Źródło:: Science (New York, N.Y.) [Science] 2022 Aug 05; Vol. 377 (6606), pp. eabq0839. Date of Electronic Publication: 2022 Aug 05.
Typ publikacji:: Journal Article
MeSH Terms:: Antibodies, Neutralizing*/immunology
Antibodies, Viral*/immunology
Betacoronavirus*/immunology
Coronavirus Infections*/prevention & control
Epitopes*/chemistry
Epitopes*/immunology
Epitopes*/therapeutic use
Nanoparticles*/therapeutic use
Spike Glycoprotein, Coronavirus*/immunology
Zoonoses*/prevention & control
Zoonoses*/virology
Animals ; Disease Models, Animal ; Macaca ; Mice ; Protein Domains/immunology ; SARS-CoV-2/immunology
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern.
Autorzy:: Almanza G; The Laboratory of Immunology, Department of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, California, United States of America.
Clark AE; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, California, United States of America.
Kouznetsova V; San Diego Supercomputer Center, University of California at San Diego, La Jolla, California, United States of America.
Olmedillas E; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, United States of America.
Castro A; Biomedical Informatics Program, University of California San Diego, La Jolla, California, United States of America.
Tsigelny IF; San Diego Supercomputer Center, University of California at San Diego, La Jolla, California, United States of America.
Wu Y; Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, and School of Basic Medical Sciences, Capital Medical University, Beijing, China.
Gao GF; Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Leibel SL; Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, California, United States of America.
Bray W; Division of Genetics, Department of Pediatrics, Center for Drug Discovery Innovation, Program in Immunology, Institute for Genomic Medicine, La Jolla, California, United States of America.
Ollmann Saphire E; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, United States of America.
Carlin AF; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, California, United States of America.
Zanetti M; The Laboratory of Immunology, Department of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, California, United States of America.; Pokaż więcej
Źródło:: PLoS pathogens [PLoS Pathog] 2022 Jul 21; Vol. 18 (7), pp. e1010686. Date of Electronic Publication: 2022 Jul 21 (Print Publication: 2022).
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Antibodies, Neutralizing*/immunology
COVID-19*/prevention & control
SARS-CoV-2*
Spike Glycoprotein, Coronavirus*/immunology
Animals ; Antibodies, Viral ; Mice ; Mice, Inbred C57BL ; Pandemics/prevention & control
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody.
Autorzy:: Yin W; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Xu Y; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Xu P; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Cao X; Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai 201203, China.
Wu C; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Gu C; Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai 201203, China.
He X; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; University of Chinese Academy of Sciences, Beijing 100049, China.
Wang X; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Huang S; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Yuan Q; The Shanghai Advanced Electron Microscope Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Wu K; The Shanghai Advanced Electron Microscope Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Hu W; The Shanghai Advanced Electron Microscope Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Huang Z; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Liu J; Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai 201203, China.
Wang Z; Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai 201203, China.
Jia F; Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai 201203, China.
Xia K; Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai 201203, China.
Liu P; Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai 201203, China.
Wang X; Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai 201203, China.
Song B; Immunological Disease Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Zheng J; Immunological Disease Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Jiang H; University of Chinese Academy of Sciences, Beijing 100049, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; School of Life Science and Technology, ShanghaiTech University, 201210 Shanghai, China.
Cheng X; University of Chinese Academy of Sciences, Beijing 100049, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Jiang Y; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; University of Chinese Academy of Sciences, Beijing 100049, China.; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Deng SJ; Shanghai Jemincare Pharmaceuticals Co., Ltd., Shanghai 201203, China.
Xu HE; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.; University of Chinese Academy of Sciences, Beijing 100049, China.; School of Life Science and Technology, ShanghaiTech University, 201210 Shanghai, China.; Pokaż więcej
Źródło:: Science (New York, N.Y.) [Science] 2022 Mar 04; Vol. 375 (6584), pp. 1048-1053. Date of Electronic Publication: 2022 Feb 08.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Angiotensin-Converting Enzyme 2/*chemistry
Antibodies, Neutralizing/*chemistry
Antibodies, Viral/*chemistry
SARS-CoV-2/*chemistry
SARS-CoV-2/*immunology
Spike Glycoprotein, Coronavirus/*chemistry
Angiotensin-Converting Enzyme 2/metabolism ; Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/metabolism ; Antibodies, Neutralizing/therapeutic use ; Antibodies, Viral/immunology ; Antibodies, Viral/metabolism ; Binding Sites ; Cryoelectron Microscopy ; Epitopes ; Humans ; Immunoglobulin Fab Fragments/chemistry ; Immunoglobulin Fab Fragments/immunology ; Immunoglobulin Fab Fragments/metabolism ; Models, Molecular ; Mutation ; Protein Binding ; Protein Conformation ; Protein Domains ; Protein Interaction Domains and Motifs ; Protein Multimerization ; Protein Subunits/chemistry ; SARS-CoV-2/genetics ; SARS-CoV-2/metabolism ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/immunology ; Spike Glycoprotein, Coronavirus/metabolism ; Thermodynamics
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies.
Autorzy:: Reincke SM; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.; Helmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab), Berlin, Germany.
Yuan M; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Kornau HC; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.; Neuroscience Research Center (NWFZ), Cluster NeuroCure, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Corman VM; Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Centre for Infection Research (DZIF), Berlin, Germany.; Labor Berlin-Charité Vivantes GmbH, Berlin.
van Hoof S; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.; Helmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab), Berlin, Germany.
Sánchez-Sendin E; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.; Helmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab), Berlin, Germany.
Ramberger M; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.; Helmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab), Berlin, Germany.
Yu W; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Hua Y; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Tien H; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Schmidt ML; Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Centre for Infection Research (DZIF), Berlin, Germany.
Schwarz T; Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Centre for Infection Research (DZIF), Berlin, Germany.
Jeworowski LM; Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Centre for Infection Research (DZIF), Berlin, Germany.
Brandl SE; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.; Helmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab), Berlin, Germany.
Rasmussen HF; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.; Helmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab), Berlin, Germany.
Homeyer MA; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.; Helmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab), Berlin, Germany.
Stöffler L; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.; Helmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab), Berlin, Germany.
Barner M; Helmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab), Berlin, Germany.
Kunkel D; Flow and Mass Cytometry Core Facility, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany.
Huo S; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Horler J; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.; Helmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab), Berlin, Germany.
von Wardenburg N; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.; Helmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab), Berlin, Germany.
Kroidl I; Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Germany.; German Center for Infection Research (DZIF), partner site Munich, Germany.
Eser TM; Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Germany.; German Center for Infection Research (DZIF), partner site Munich, Germany.
Wieser A; Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Germany.; German Center for Infection Research (DZIF), partner site Munich, Germany.
Geldmacher C; Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Germany.; German Center for Infection Research (DZIF), partner site Munich, Germany.
Hoelscher M; Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Germany.; German Center for Infection Research (DZIF), partner site Munich, Germany.
Gänzer H; Department of Internal Medicine, BKH Schwaz, Schwaz, Austria.
Weiss G; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
Schmitz D; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.; Neuroscience Research Center (NWFZ), Cluster NeuroCure, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Drosten C; Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Centre for Infection Research (DZIF), Berlin, Germany.
Prüss H; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.; Helmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab), Berlin, Germany.
Wilson IA; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.; The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Kreye J; Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.; Helmholtz Innovation Lab BaoBab (Brain Antibody-omics and B-cell Lab), Berlin, Germany.; Department of Pediatric Neurology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; Pokaż więcej
Źródło:: Science (New York, N.Y.) [Science] 2022 Feb 18; Vol. 375 (6582), pp. 782-787. Date of Electronic Publication: 2022 Jan 25.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:: Cross Reactions*
Antibodies, Neutralizing/*immunology
Antibodies, Viral/*immunology
COVID-19/*immunology
SARS-CoV-2/*immunology
Spike Glycoprotein, Coronavirus/*immunology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Neutralizing/chemistry ; Antibodies, Neutralizing/genetics ; Antibodies, Viral/genetics ; Antibodies, Viral/metabolism ; Antigenic Drift and Shift ; COVID-19/virology ; Female ; Humans ; Male ; Middle Aged ; Neutralization Tests ; Protein Binding ; Protein Domains ; Protein Interaction Domains and Motifs ; SARS-CoV-2/chemistry ; SARS-CoV-2/genetics ; Spike Glycoprotein, Coronavirus/chemistry ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/metabolism
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Analysis of the Neutralizing Activity of Antibodies Targeting Open or Closed SARS-CoV-2 Spike Protein Conformations.
Autorzy:: Cia G; Computational Biology and Bioinformatics, Université Libre de Bruxelles, 1050 Brussels, Belgium.; Interuniversity Institute of Bioinformatics in Brussels, 1050 Brussels, Belgium.
Pucci F; Computational Biology and Bioinformatics, Université Libre de Bruxelles, 1050 Brussels, Belgium.; Interuniversity Institute of Bioinformatics in Brussels, 1050 Brussels, Belgium.
Rooman M; Computational Biology and Bioinformatics, Université Libre de Bruxelles, 1050 Brussels, Belgium.; Interuniversity Institute of Bioinformatics in Brussels, 1050 Brussels, Belgium.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2022 Feb 14; Vol. 23 (4). Date of Electronic Publication: 2022 Feb 14.
Typ publikacji:: Journal Article
MeSH Terms:: Antibodies, Neutralizing/*immunology
SARS-CoV-2/*metabolism
Spike Glycoprotein, Coronavirus/*immunology
Angiotensin-Converting Enzyme 2/chemistry ; Angiotensin-Converting Enzyme 2/metabolism ; Antibodies, Monoclonal/immunology ; Antigen-Antibody Reactions ; COVID-19/pathology ; COVID-19/virology ; Epitopes/immunology ; Humans ; Mutagenesis ; Protein Binding ; Protein Conformation ; SARS-CoV-2/isolation & purification ; Spike Glycoprotein, Coronavirus/chemistry ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/metabolism
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: The E484K Substitution in a SARS-CoV-2 Spike Protein Subunit Vaccine Resulted in Limited Cross-Reactive Neutralizing Antibody Responses in Mice.
Autorzy:: Hu L; State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Science, Guangzhou Medical University, Guangzhou 511436, China.
Xu Y; Guangdong South China Vaccine Co., Ltd., Guangzhou 510663, China.
Wu L; State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Science, Guangzhou Medical University, Guangzhou 511436, China.
Feng J; State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Science, Guangzhou Medical University, Guangzhou 511436, China.; Guangdong South China Vaccine Co., Ltd., Guangzhou 510663, China.; Guangzhou Laboratory, No. 9 XingDaoHuanBei Road, Guangzhou International Bio Island, Guangzhou 510005, China.
Zhang L; Guangzhou Customs District Technology Center, Guangzhou 510665, China.
Tang Y; State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Science, Guangzhou Medical University, Guangzhou 511436, China.
Zhao X; State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Science, Guangzhou Medical University, Guangzhou 511436, China.
Mai R; Guangdong South China Vaccine Co., Ltd., Guangzhou 510663, China.
Chen L; Guangdong South China Vaccine Co., Ltd., Guangzhou 510663, China.
Mei L; State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Science, Guangzhou Medical University, Guangzhou 511436, China.
Tan Y; Guangdong South China Vaccine Co., Ltd., Guangzhou 510663, China.
Du Y; Guangdong South China Vaccine Co., Ltd., Guangzhou 510663, China.
Zhen Y; Guangdong South China Vaccine Co., Ltd., Guangzhou 510663, China.
Su W; Guangdong South China Vaccine Co., Ltd., Guangzhou 510663, China.
Peng T; State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Science, Guangzhou Medical University, Guangzhou 511436, China.; Guangdong South China Vaccine Co., Ltd., Guangzhou 510663, China.; Pokaż więcej
Źródło:: Viruses [Viruses] 2022 Apr 21; Vol. 14 (5). Date of Electronic Publication: 2022 Apr 21.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antibodies, Neutralizing*/immunology
COVID-19*/prevention & control
COVID-19 Vaccines*/genetics
COVID-19 Vaccines*/immunology
Cross Reactions*
Spike Glycoprotein, Coronavirus*/genetics
Animals ; Antibodies, Viral/immunology ; Mice ; SARS-CoV-2/genetics ; Vaccines, Subunit/genetics ; Vaccines, Subunit/immunology
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain.
Autorzy:: Nabel KG; Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Clark SA; Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Shankar S; Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Pan J; Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Clark LE; Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Yang P; Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Coscia A; Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
McKay LGA; Department of Microbiology and National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, MA 02118, USA.
Varnum HH; Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Brusic V; Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
Tolan NV; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Zhou G; Center for Clinical Investigation, Brigham and Women's Hospital, Boston, MA 02115, USA.
Desjardins M; Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.; Division of Infectious Diseases, Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal QC H2X 0C1, Canada.
Turbett SE; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
Kanjilal S; Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA 02215, USA.
Sherman AC; Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Dighe A; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
LaRocque RC; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Ryan ET; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA.
Tylek C; AbbVie Bioresearch Center, Worcester, MA 01605, USA.
Cohen-Solal JF; AbbVie Bioresearch Center, Worcester, MA 01605, USA.
Darcy AT; AbbVie Bioresearch Center, Worcester, MA 01605, USA.
Tavella D; AbbVie Bioresearch Center, Worcester, MA 01605, USA.
Clabbers A; AbbVie Bioresearch Center, Worcester, MA 01605, USA.
Fan Y; AbbVie Bioresearch Center, Worcester, MA 01605, USA.
Griffiths A; Department of Microbiology and National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, MA 02118, USA.
Correia IR; AbbVie Bioresearch Center, Worcester, MA 01605, USA.
Seagal J; AbbVie Bioresearch Center, Worcester, MA 01605, USA.
Baden LR; Center for Clinical Investigation, Brigham and Women's Hospital, Boston, MA 02115, USA.; Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.; Massachusetts Consortium on Pathogen Readiness, Boston, MA, USA.
Charles RC; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Abraham J; Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.; Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.; Massachusetts Consortium on Pathogen Readiness, Boston, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Pokaż więcej
Źródło:: Science (New York, N.Y.) [Science] 2022 Jan 21; Vol. 375 (6578), pp. eabl6251. Date of Electronic Publication: 2022 Jan 21.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:: Immune Evasion*
Antibodies, Neutralizing/*immunology
Antibodies, Viral/*immunology
SARS-CoV-2/*immunology
Spike Glycoprotein, Coronavirus/*chemistry
Spike Glycoprotein, Coronavirus/*immunology
Angiotensin-Converting Enzyme 2/chemistry ; Angiotensin-Converting Enzyme 2/metabolism ; BNT162 Vaccine/immunology ; Betacoronavirus/immunology ; COVID-19/immunology ; COVID-19/virology ; Cross Reactions ; Cryoelectron Microscopy ; Crystallography, X-Ray ; Epitopes ; Evolution, Molecular ; Humans ; Models, Molecular ; Mutation ; Polysaccharides/analysis ; Protein Binding ; Protein Domains ; Receptors, Coronavirus/chemistry ; Receptors, Coronavirus/metabolism ; SARS-CoV-2/genetics ; Spike Glycoprotein, Coronavirus/genetics ; Viral Pseudotyping
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity.
Autorzy:: Zhou W; School of Life Science and Technology, Harbin Institute of Technology, Harbin 150000, China.
Xu C; School of Life Science and Technology, Harbin Institute of Technology, Harbin 150000, China.
Wang P; School of Life Science and Technology, Harbin Institute of Technology, Harbin 150000, China.
Anashkina AA; Engelhardt Institute of Molecular Biology RAS, Vavilova, 32, Moscow 119991, Russia.
Jiang Q; School of Life Science and Technology, Harbin Institute of Technology, Harbin 150000, China.; Pokaż więcej
Źródło:: Briefings in bioinformatics [Brief Bioinform] 2022 Jan 17; Vol. 23 (1).
Typ publikacji:: Journal Article
MeSH Terms:: COVID-19*/genetics
COVID-19*/immunology
Mutation*
SARS-CoV-2*/genetics
SARS-CoV-2*/immunology
Spike Glycoprotein, Coronavirus*/genetics
Spike Glycoprotein, Coronavirus*/immunology
Antibodies, Neutralizing/*immunology
Antibodies, Viral/*immunology
Humans

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Exploring the immune evasion of SARS-CoV-2 variant harboring E484K by molecular dynamics simulations.
Autorzy:: Wu L; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.; School of Pharmacy, University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China.
Peng C; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.; School of Pharmacy, University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China.
Yang Y; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.; School of Pharmacy, University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China.
Shi Y; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.; School of Pharmacy, University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China.
Zhou L; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.; School of Pharmacy, University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China.
Xu Z; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.; School of Pharmacy, University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China.
Zhu W; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.; School of Pharmacy, University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China.; Pokaż więcej
Źródło:: Briefings in bioinformatics [Brief Bioinform] 2022 Jan 17; Vol. 23 (1).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antibodies, Neutralizing*/chemistry
Antibodies, Neutralizing*/immunology
Antibodies, Viral*/chemistry
Antibodies, Viral*/immunology
Immune Evasion*
Molecular Dynamics Simulation*
Mutation, Missense*
SARS-CoV-2*/chemistry
SARS-CoV-2*/genetics
SARS-CoV-2*/immunology
Spike Glycoprotein, Coronavirus*/chemistry
Spike Glycoprotein, Coronavirus*/genetics
Spike Glycoprotein, Coronavirus*/immunology
Amino Acid Substitution ; Humans
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2.
Autorzy:: Kim GN; Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.
Choi JA; International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Korea.
Wu K; Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.
Saeedian N; Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.
Yang E; International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Korea.
Park H; International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Korea.
Woo SJ; International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Korea.
Lim G; International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Korea.
Kim SG; International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Korea.
Eo SK; International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Korea.
Jeong HW; International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Korea.
Kim T; International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Korea.
Chang JH; International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Korea.
Seo SH; International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Korea.
Kim NH; Sumagen, 4F Dongwon Bldg, Teheran-ro 77-gil, Gangnam-gu, Seoul, Korea.
Choi E; Sumagen, 4F Dongwon Bldg, Teheran-ro 77-gil, Gangnam-gu, Seoul, Korea.
Choo S; Sumagen, 4F Dongwon Bldg, Teheran-ro 77-gil, Gangnam-gu, Seoul, Korea.
Lee S; Sumagen, 4F Dongwon Bldg, Teheran-ro 77-gil, Gangnam-gu, Seoul, Korea.
Winterborn A; Animal Facility, Queen's University, Kinston, Ontario, Canada.
Li Y; Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.
Parham K; Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.
Donovan JM; Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.
Fenton B; Department of Biology, Faculty of Science, The University of Western Ontario, London, Ontario, Canada.
Dikeakos JD; Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.
Dekaban GA; Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.; Molecular Medicine Research Laboratories, Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.
Haeryfar SMM; Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.
Troyer RM; Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.
Arts EJ; Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.
Barr SD; Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.
Song M; International Vaccine Institute, SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul, Korea.
Kang CY; Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, Canada.; Pokaż więcej
Źródło:: PLoS pathogens [PLoS Pathog] 2021 Dec 16; Vol. 17 (12), pp. e1010092. Date of Electronic Publication: 2021 Dec 16 (Print Publication: 2021).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Angiotensin-Converting Enzyme 2/*metabolism
Antibodies, Neutralizing/*immunology
Antibodies, Viral/*immunology
COVID-19/*prevention & control
COVID-19 Vaccines/*administration & dosage
Spike Glycoprotein, Coronavirus/*immunology
Vesicular stomatitis Indiana virus/*genetics
Angiotensin-Converting Enzyme 2/genetics ; Animals ; COVID-19/immunology ; COVID-19/virology ; COVID-19 Vaccines/genetics ; Chlorocebus aethiops ; Humans ; Immunization ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/metabolism ; Vero Cells ; Viral Proteins/genetics ; Viral Proteins/immunology

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity.
Autorzy:: Neerukonda SN; Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA.
Vassell R; Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA.
Lusvarghi S; Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA.
Wang R; Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA.
Echegaray F; Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Bentley L; Office of the Assistance Secretary for Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC 20201, USA.
Eakin AE; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, MD 20892, USA.
Erlandson KJ; Influenza and Emerging Infectious Diseases Division, Biomedical Advanced Research and Development Authority, U.S. Department of Health and Human Services, Washington, DC 20201, USA.
Katzelnick LC; Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Weiss CD; Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA.
Wang W; Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA.; Pokaż więcej
Źródło:: Viruses [Viruses] 2021 Dec 11; Vol. 13 (12). Date of Electronic Publication: 2021 Dec 11.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms:: Antibodies, Neutralizing/*immunology
SARS-CoV-2/*immunology
Spike Glycoprotein, Coronavirus/*metabolism
Angiotensin-Converting Enzyme 2/metabolism ; Antibodies, Viral/immunology ; Antigenic Variation ; COVID-19/immunology ; COVID-19/virology ; COVID-19 Vaccines/immunology ; Cell Fusion ; Furin/metabolism ; Humans ; Protein Binding ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/immunology
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding.
Autorzy:: Bozdaganyan ME; Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.; N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, 119991 Moscow, Russia.; Faculty of Biology, Shenzhen MSU-BIT University, Shenzhen 518172, China.
Shaitan KV; Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.; N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, 119991 Moscow, Russia.
Kirpichnikov MP; Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.
Sokolova OS; Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.; Faculty of Biology, Shenzhen MSU-BIT University, Shenzhen 518172, China.
Orekhov PS; Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.; Faculty of Biology, Shenzhen MSU-BIT University, Shenzhen 518172, China.; Institute of Personalized Medicine, Sechenov University, 119146 Moscow, Russia.; Pokaż więcej
Źródło:: Viruses [Viruses] 2022 Jan 30; Vol. 14 (2). Date of Electronic Publication: 2022 Jan 30.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Mutation*
Antibodies, Neutralizing/*metabolism
Antibodies, Viral/*metabolism
Binding Sites, Antibody/*genetics
Computational Biology/*methods
SARS-CoV-2/*genetics
Spike Glycoprotein, Coronavirus/*genetics
Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; Epitopes/metabolism ; Host Microbial Interactions/genetics ; Humans ; Protein Binding ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/immunology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Novel Neutralizing Epitope of PEDV S1 Protein Identified by IgM Monoclonal Antibody.
Autorzy:: Thavorasak T; Graduate Program in Immunology, Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.; Center of Research Excellence on Therapeutic Proteins and Antibody Engineering, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Chulanetra M; Center of Research Excellence on Therapeutic Proteins and Antibody Engineering, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Glab-Ampai K; Center of Research Excellence on Therapeutic Proteins and Antibody Engineering, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Teeranitayatarn K; MORENA Solution Company, Wang-thong-lang District, Bangkok 10310, Thailand.
Songserm T; Department of Veterinary Pathology, Faculty of Veterinary Medicine, Kam-paeng-san Campus, Kasetsart University, Nakhon-pathom 73140, Thailand.
Yodsheewan R; Department of Veterinary Pathology, Faculty of Veterinary Medicine, Kam-paeng-san Campus, Kasetsart University, Nakhon-pathom 73140, Thailand.
Sae-Lim N; Center of Research Excellence on Therapeutic Proteins and Antibody Engineering, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Lekcharoensuk P; Department of Microbiology and Immunology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand.
Sookrung N; Center of Research Excellence on Therapeutic Proteins and Antibody Engineering, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.; Biomedical Research Incubation Unit, Department of Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.
Chaicumpa W; Center of Research Excellence on Therapeutic Proteins and Antibody Engineering, Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand.; Pokaż więcej
Źródło:: Viruses [Viruses] 2022 Jan 11; Vol. 14 (1). Date of Electronic Publication: 2022 Jan 11.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antibodies, Monoclonal/*immunology
Antibodies, Neutralizing/*immunology
Antibodies, Viral/*immunology
Epitopes/*immunology
Immunoglobulin M/*immunology
Porcine epidemic diarrhea virus/*immunology
Spike Glycoprotein, Coronavirus/*immunology
Animals ; Chlorocebus aethiops ; Enzyme-Linked Immunosorbent Assay ; Female ; HeLa Cells ; Humans ; Immunization, Passive ; Mice ; Mice, Inbred BALB C ; Neutralization Tests ; Sequence Alignment ; Spike Glycoprotein, Coronavirus/genetics ; Swine ; Swine Diseases/immunology ; Vero Cells

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Correlation of vaccine-elicited antibody levels and neutralizing activities against SARS-CoV-2 and its variants.
Autorzy:: Liu J; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Bodnar BH; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.; Center for Metabolic Disease Research, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Padhiar NH; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Khan AI; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Meng F; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Saribas S; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.; Center for Metabolic Disease Research, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Wang P; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Wang X; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
McCluskey E; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Shah S; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.; Center for Metabolic Disease Research, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Zhao H; Department of Biomedical Education and Data Science, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Luo JJ; Department of Neurology, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Hu WH; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.; Center for Metabolic Disease Research, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.
Ho WZ; Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.; Pokaż więcej
Źródło:: Clinical and translational medicine [Clin Transl Med] 2021 Dec; Vol. 11 (12), pp. e644.
Typ publikacji:: Letter
MeSH Terms:: 2019-nCoV Vaccine mRNA-1273/*immunology
Antibodies, Neutralizing/*immunology
Antibodies, Viral/*immunology
BNT162 Vaccine/*immunology
COVID-19/*immunology
Immunoglobulin G/*immunology
SARS-CoV-2/*immunology
Spike Glycoprotein, Coronavirus/*immunology
2019-nCoV Vaccine mRNA-1273/administration & dosage ; BNT162 Vaccine/administration & dosage ; COVID-19/blood ; COVID-19/genetics ; COVID-19/prevention & control ; Female ; Humans ; Male ; SARS-CoV-2/genetics ; SARS-CoV-2/metabolism ; Spike Glycoprotein, Coronavirus/genetics
SCR Organism:: SARS-CoV-2 variants

Opinia redakcyjna

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Antibody cocktail effective against variants of SARS-CoV-2.
Autorzy:: Liang KH; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11529, Taiwan.; Institute of Cellular and Organismic Biology, Academia Sinica, No. 128, Academia Road, Section 2, Nankang, Taipei, 11529, Taiwan.
Chiang PY; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11529, Taiwan.
Ko SH; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11529, Taiwan.
Chou YC; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11529, Taiwan.
Lu RM; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11529, Taiwan.
Lin HT; Institute of Cellular and Organismic Biology, Academia Sinica, No. 128, Academia Road, Section 2, Nankang, Taipei, 11529, Taiwan.
Chen WY; Institute of Cellular and Organismic Biology, Academia Sinica, No. 128, Academia Road, Section 2, Nankang, Taipei, 11529, Taiwan.
Lin YL; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11529, Taiwan.; Institute of Biomedical Sciences, Academia Sinica, Taipei, 11529, Taiwan.
Tao MH; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11529, Taiwan.; Institute of Biomedical Sciences, Academia Sinica, Taipei, 11529, Taiwan.
Jan JT; Genomics Research Center, Academia Sinica, Taipei, 11529, Taiwan.
Wu HC; Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, 11529, Taiwan. .; Institute of Cellular and Organismic Biology, Academia Sinica, No. 128, Academia Road, Section 2, Nankang, Taipei, 11529, Taiwan. .; Pokaż więcej
Źródło:: Journal of biomedical science [J Biomed Sci] 2021 Nov 23; Vol. 28 (1), pp. 80. Date of Electronic Publication: 2021 Nov 23.
Typ publikacji:: Journal Article
MeSH Terms:: Antibodies, Neutralizing/*immunology
Antibodies, Viral/*immunology
COVID-19/*immunology
SARS-CoV-2/*immunology
Spike Glycoprotein, Coronavirus/*immunology
Animals ; Antibodies, Neutralizing/therapeutic use ; Antibodies, Viral/therapeutic use ; COVID-19/genetics ; Humans ; Rabbits ; SARS-CoV-2/genetics ; Spike Glycoprotein, Coronavirus/genetics ; COVID-19 Drug Treatment

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Computational redesign of Fab CC12.3 with substantially better predicted binding affinity to SARS-CoV-2 than human ACE2 receptor.
Autorzy:: Treewattanawong W; Structural and Computational Biology Research Unit, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand.
Sitthiyotha T; Structural and Computational Biology Research Unit, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand.
Chunsrivirot S; Structural and Computational Biology Research Unit, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand. .; Department of Biochemistry, Faculty of Science, Chulalongkorn University, Pathumwan, Bangkok, 10330, Thailand. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2021 Nov 12; Vol. 11 (1), pp. 22202. Date of Electronic Publication: 2021 Nov 12.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Angiotensin-Converting Enzyme 2/*metabolism
Antibodies, Neutralizing/*metabolism
COVID-19/*metabolism
Immunoglobulin Fab Fragments/*metabolism
SARS-CoV-2/*metabolism
Spike Glycoprotein, Coronavirus/*metabolism
Angiotensin-Converting Enzyme 2/chemistry ; Antibodies, Neutralizing/chemistry ; Binding Sites ; Humans ; Immunoglobulin Fab Fragments/chemistry ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Protein Binding ; Protein Domains ; SARS-CoV-2/chemistry ; Spike Glycoprotein, Coronavirus/chemistry

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Spike Glycoprotein, Coronavirus"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język